PUREfi Wealth LLC Invests $32,000 in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

PUREfi Wealth LLC bought a new position in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 10,000 shares of the company’s stock, valued at approximately $32,000.

Other institutional investors have also modified their holdings of the company. Virtu Financial LLC acquired a new stake in Checkpoint Therapeutics in the third quarter valued at approximately $30,000. Bartlett & CO. Wealth Management LLC grew its position in Checkpoint Therapeutics by 375.0% in the fourth quarter. Bartlett & CO. Wealth Management LLC now owns 19,000 shares of the company’s stock valued at $61,000 after acquiring an additional 15,000 shares in the last quarter. Gladstone Institutional Advisory LLC grew its position in Checkpoint Therapeutics by 141.4% in the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 20,500 shares in the last quarter. Walleye Capital LLC acquired a new stake in Checkpoint Therapeutics in the third quarter valued at approximately $148,000. Finally, State Street Corp grew its position in Checkpoint Therapeutics by 32.2% in the third quarter. State Street Corp now owns 94,424 shares of the company’s stock valued at $212,000 after acquiring an additional 23,000 shares in the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Insider Activity

In related news, CEO James F. Oliviero III sold 220,230 shares of the firm’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $3.38, for a total transaction of $744,377.40. Following the transaction, the chief executive officer now directly owns 3,194,583 shares in the company, valued at $10,797,690.54. This trade represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO William Garrett Gray sold 268,432 shares of the firm’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total value of $1,076,412.32. Following the transaction, the chief financial officer now owns 1,032,754 shares in the company, valued at $4,141,343.54. This trade represents a 20.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 582,336 shares of company stock worth $2,156,801. 2.10% of the stock is currently owned by insiders.

Checkpoint Therapeutics Trading Down 4.3 %

Checkpoint Therapeutics stock opened at $3.31 on Friday. The stock has a market cap of $161.63 million, a P/E ratio of -1.80 and a beta of 1.36. The stock has a 50 day moving average of $3.35 and a 200-day moving average of $3.01. Checkpoint Therapeutics, Inc. has a 52 week low of $1.38 and a 52 week high of $4.50.

Analysts Set New Price Targets

CKPT has been the subject of several recent research reports. Lake Street Capital increased their price objective on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, December 16th. D. Boral Capital began coverage on Checkpoint Therapeutics in a research note on Monday, January 13th. They set a “buy” rating and a $9.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research note on Monday, December 16th.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.